Matthew Bohm
A5064122870- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Gastrointestinal motility and disorders
- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Helicobacter pylori-related gastroenterology studies
- Celiac Disease Research and Management
- Nosocomial Infections in ICU
- Liver Diseases and Immunity
- Gastric Cancer Management and Outcomes
- Diet and metabolism studies
- Colorectal Cancer Screening and Detection
- Clinical Nutrition and Gastroenterology
- Diverticular Disease and Complications
- Health Systems, Economic Evaluations, Quality of Life
- Eosinophilic Disorders and Syndromes
- Autoimmune and Inflammatory Disorders
- Gastrointestinal disorders and treatments
- Biosimilars and Bioanalytical Methods
- Digestive system and related health
- Immunodeficiency and Autoimmune Disorders
- Pregnancy and Medication Impact
- Esophageal and GI Pathology
- Diagnosis and treatment of tuberculosis
Indiana University School of Medicine
2016-2024
Indiana University
2017-2024
University School
2018-2024
Indiana University – Purdue University Indianapolis
2014-2024
Perrigo (United States)
2024
Bristol-Myers Squibb (Switzerland)
2024
Entasis Therapeutics (United States)
2024
AbbVie (United States)
2024
Pfizer (United States)
2024
Janssen (Belgium)
2024
Severe and severe-complicated Clostridium difficile infection (CDI) is associated with high morbidity mortality. Colectomy standard of care; however, post-surgical mortality rates approach 50%. Case reports suggest fecal microbiota transplant (FMT) a promising treatment severe disease but there paucity data. Here, we present single center experience novel sequential FMT protocol for patients refractory to maximal medical therapy. This consists at least one delivered via colonoscopy criteria...
We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, identify predictors response treatment.Retrospective review (May 2014-December 2016) VICTORY Consortium data. Adults with follow-up after starting VDZ clinically active UC were included. Primary outcomes cumulative rates clinical remission (resolution all UC-related symptoms) endoscopic (Mayo sub-score 0). Key secondary included corticosteroid-free deep (clinical remission). Cox proportional hazard...
As more treatment options for inflammatory bowel diseases become available, it is important to identify patients most likely respond different therapies. We created and validated a scoring system with Crohn's disease (CD) who vedolizumab.
We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD).This study used a retrospective, multicenter, multinational consortium UST-treated CD patients. Data included patient demographics, phenotype, activity, treatment history, concomitant medications. Cumulative rates clinical, steroid-free, endoscopic, radiographic remissions were assessed using time-to-event analysis, clinical predictors by multivariate Cox proportional hazard...
There are few real-world data on the safety of vedolizumab for treatment Crohn's disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious non-infectious adverse events in clinical practice.We performed a retrospective review from multicenter consortium database (from May 2014 through June 2017). Infectious were defined as those requiring antibiotics, hospitalization, discontinuation, resulting death. Rates proportions per...
Background & AimsWe created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC).MethodsWe performed logistic regression analyses data from the GEMINI 1 trial, 620 patients with UC who received induction maintenance (derivation cohort), identify factors associated corticosteroid-free remission (full Mayo score 2 or less, no subscore above 1). We used these develop model treatment, which we called CDST. evaluated...
Abstract Background We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness VDZ dose intensification for managing LOR. Methods Retrospective review (May 2014–December 2016) a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates were used determine rates LOR . Independent predictors identified using univariate multivariable Cox proportional hazard regression. Success recapturing (>50% reduction...
Summary Background Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)‐antagonist therapy in Crohn's disease (CD). Aim To compare safety effectiveness of TNF‐antagonist adult CD patients. Methods Retrospective observational cohort (May 2014–December 2017) propensity score‐weighted comparison vs (infliximab, adalimumab, certolizumab) CD. Propensity scores were weighted for age, prior treatments, complications, extent severity, steroid dependence, concomitant...
Background & AimsPatients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates response to tumor necrosis factor (TNF) antagonists than patients longer duration. Little is known about the association between and other biologic agents. We aimed evaluate CD or UC vedolizumab, stratified by duration.MethodsWe analyzed data from a retrospective, multicenter, consortium (n = 650) 437) treated vedolizumab May 2014 through December 2016. Using time event...
We aimed to compare safety and effectiveness of vedolizumab tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis routine practice.A multicenter, retrospective, observational cohort study (May 2014 December 2017) patients treated with or TNF-antagonist therapy. Propensity score weighted comparisons for development serious adverse events achievement clinical remission, steroid-free deep remission. A priori determined subgroup TNF-antagonist-naïve -exposed patients, against...
In two separate cohorts, intestinal resection for Crohn's disease was associated with reduced alpha diversity and increased Proteobacteria Bacteroidetes Firmicutes.Surgery also decreased abundance of bai operon genes secondary bile acids, including isoLCA.
Triplicate groups of pike perch (Sander lucioperca) juveniles were fed six experimental diets containing protein levels varying from 263 to 619 g kg−1 dry matter (d.m.) for 56 days. Dietary was supplied by graded amounts fish meal (with 720 crude protein). Crude lipid and gross energy content 101–107 19.9–20.6 MJ remained constant between diets. Pike with an initial body weight 1.05 ± 0.05 randomly distributed in 18 tanks two similar recirculation systems on gradually decreasing feeding...
The goal of this article is to present the results long-term treatment with esophageal dilation a consecutive series adults eosinophilic esophagitis (EoE). EoE in disease middle aged white males, recurrent food impactions and dysphagia. exact unknown due uncertainty pathogenesis. Currently, follow-up adult patients limited. Sixteen (12 males/4 females between ages 27 58 years) underwent detailed history baseline upper gastrointestinal endoscopy (EGD) multiple biopsies. Thirteen had dilation....
Summary Background A clinical decision support tool (CDST) has been validated for predicting treatment effectiveness of vedolizumab (VDZ) in Crohn’s disease. Aim To assess the utility this CDST exposure‐efficacy and disease outcomes. Methods Using data from three independent datasets (GEMINI, GETAID VICTORY), we assessed remission rates measured VDZ exposure, rapidity onset action, response to dose optimisation progression surgery by CDST‐defined groups (low, intermediate high). Results...
Recurrent Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD) is a clinical challenge. Fecal microbiota transplantation (FMT) has emerged as recurrent CDI therapy. Anecdotal concerns exist regarding worsening of IBD activity; however, prospective data among are limited. Secondary analysis from an open-label, prospective, multicenter cohort study 2 or more episodes was performed. Participants underwent single FMT by colonoscopy (250 mL, healthy universal...
Abstract Background Clinical and molecular subcategories of inflammatory bowel disease (IBD) are needed to discover mechanisms predictors response relapse. We aimed develop a study prospective adult research cohort with IBD (SPARC IBD) including longitudinal clinical patient-reported data biosamples. Methods established adults from geographically diverse sample patients across the United States standardized biosample collection methods processing techniques. At enrollment at time lower...
Background: Eosinophilic esophagitis is a chronic inflammatory disease with mucosal accumulation of eosinophils. There paucity data among racial/ethnic groups other than white patients. Aim: To determine if differences exist in clinical presentation, endoscopic appearance, and biopsy results adult patients (age ≥18 y) eosinophilia examine the prevalence at an urban hospital over 10-year period. Methods: Pathology reports searched Temple University Hospital 2000 to 2009; key words:...